Figure 2.

(a) Study design for the denosumab dose ranging trial and (b) resulting mean lumbar spine bone mineral density percent change, (c) median serum C-telopeptide, and (d) median serum bone-specific alkaline phosphatase. Treatment groups are placebo (black), 30 mg every 3 months for 8 doses and changed to 60 mg every 6 months starting on month 36 (red); 210 mg every 6 months for four doses then discontinued (purple), and the active control, Alendronate (yellow). Reprinted from Miller et al.¹⁴